Prescribing Buprenorphine

Why Buprenorphine Matters

Opioid overdose kills more Americans than car crashes. The single most effective thing you can do to prevent those deaths is prescribe buprenorphine, and, as of January 2023, you can do it with nothing more than your existing DEA registration. No X-waiver. No patient cap. No separate application. The regulatory wall that kept most clinicians out of addiction medicine for twenty years is gone.

Buprenorphine is a partial mu-opioid agonist, and that single pharmacologic fact is why it has become the gold-standard office-based treatment for opioid use disorder (OUD). Because it only partially activates the mu receptor, it has a ceiling effect on respiratory depression: past a certain dose, giving more does not further suppress breathing. That is the property that makes it dramatically safer than methadone or heroin and safe enough to hand to a patient to take home. It occupies the mu receptor with very high affinity and a long half-life, so it holds cravings and withdrawal at bay for a full day or more while blunting the reinforcing "high" of other opioids that try to compete for the same receptor.

The evidence is not subtle. Medication treatment, buprenorphine or methadone, outperforms every other single intervention for opioid dependence, including counseling alone. Buprenorphine at adequate dose matches methadone's efficacy. And the mortality data are stark: stopping OUD medication raises mortality roughly six-fold in the following month. Staying on it saves lives on a timescale of weeks.

Yet buprenorphine remains underprescribed, and the reasons are almost never clinical. They are fear of precipitated withdrawal during induction, discomfort prescribing a controlled substance to people with addiction, worry about diversion, and uncertainty about office logistics. This guide is built to dismantle each of those fears.

A note on where this drug came from: buprenorphine was synthesized decades ago as an analgesic, but its second life, as OUD treatment, was formalized by the DATA 2000 legislation and the October 2002 FDA approval of Suboxone (buprenorphine/naloxone). For two decades the "X-waiver" gated who could prescribe it. That gate is now open. The question is no longer may you prescribe buprenorphine. It is whether you will learn to.

Part 1: Indications, Who Is Buprenorphine For?

FDA-Approved Uses

• Opioid use disorder (OUD): maintenance and, secondarily, medically supervised withdrawal (approved October 8, 2002).
• The defining advantage over methadone: office-based prescribing by individual clinicians, rather than treatment only within a federally licensed opioid treatment program (OTP).

The Evidence-Based Clinical Uses

OUD maintenance, the home turf. This is where buprenorphine belongs and where the evidence is deepest. The pivotal 52-week trial (Fudala, NEJM 2003) established superiority to placebo on opioid-negative urine screens. Subsequent work showed non-inferiority to methadone at 17 weeks and 6 months (Kakko, 2007), and real-world effectiveness in ordinary primary-care settings (Cunningham, 2008). The critical caveat: this equivalence to methadone holds only at adequate dose, ≥16 mg/day. Underdosed buprenorphine underperforms; that is a dosing failure, not a drug failure.

Both prescription-opioid and heroin dependence. Buprenorphine works across the OUD spectrum: patients who became dependent on prescribed oxycodone respond as well as those using heroin.

Patients with cardiopulmonary disease. The respiratory ceiling makes buprenorphine the safer agonist choice for patients whose lungs or hearts can't tolerate the dose-dependent respiratory depression of a full agonist.

Best Candidates

• OUD patients who can wait for spontaneous withdrawal to reach COWS ≥8–10 before induction
• Patients who value the independence of office-based care (work, travel, rural residence): the quality-of-life gap over daily-clinic methadone is enormous
• Pregnant patients with OUD (see Special Populations: buprenorphine is preferred over methadone in many algorithms)
• Patients with respiratory or cardiac disease

Where Buprenorphine Struggles

• Very high-dose, long-term full-agonist users may not achieve adequate relief from a partial agonist and may do better on methadone. Partial agonism has a ceiling on efficacy too, not just on safety.
• Patients who cannot tolerate any withdrawal window before induction: here a microinduction approach (below) or a different setting is needed.
• Unstable induction environments: active cognitive impairment, unstable housing, or concurrent alcohol/benzodiazepine withdrawal argue for ED or inpatient induction rather than home.

The Off-Label Territory (Know the Limits)

• Chronic pain: low-dose transdermal/buccal buprenorphine is used and FDA-approved for pain in those specific formulations; the sublingual OUD product is not a pain drug, and evidence for it in pain is insufficient.
• Treatment-resistant depression: buprenorphine monotherapy was fast-tracked but failed FDA approval on efficacy (only 2 of 4 trials positive, with methodologic problems). Not a depression drug.
• Severe acute suicidal ideation: a small Israeli RCT (n=62) found ultra-low-dose buprenorphine (0.1–0.8 mg/day, mean ~0.44 mg) reduced Beck suicidality scores over 4 weeks, with no withdrawal on abrupt stop. Intriguing, not established practice.

Part 2: Before You Start, Workup and Candidacy

The Refreshingly Short Lab List

For otherwise healthy patients, no pre-treatment labs are required. The historical panel (CBC, LFTs, electrolytes, renal function, ECG) has been reassessed as unnecessary and is no longer standard. This removes one of the classic excuses for delay. You can induct a patient the day they present.

What is still worth doing:

Key Pre-Start Questions

• What opioid, how much, how recently? This sets your induction timing (heroin ~12h, long-acting agents ≥24h) and flags whether adequate withdrawal is achievable before the visit.
• Any benzodiazepines, alcohol, or other CNS depressants? These do not contraindicate buprenorphine, but they raise the respiratory-depression stakes and may move induction to a monitored setting.
• Is the home environment stable enough for home induction? Unstable housing, cognitive impairment, or concurrent alcohol/benzo withdrawal → ED or inpatient.

The Treatment Agreement

A written treatment agreement (templates are available, including from Carlat) sets expectations up front: no early refills, urine screens as part of care, appointment attendance, single-prescriber sourcing. Frame it as a shared plan, not a threat.

Part 3: How to Start and Dose

The induction is the technically demanding part; maintenance is straightforward. Get induction right and the rest is monitoring and dose adjustment.

Formulations, What to Prescribe

• Sublingual buprenorphine/naloxone (Suboxone and generics): first-line for essentially everyone. The 4:1 buprenorphine:naloxone ratio exists for abuse deterrence: taken sublingually, naloxone is poorly absorbed and inert; if the product is crushed and injected, the naloxone becomes active and precipitates withdrawal. Available as 2 mg and 8 mg films/tablets.
• Buprenorphine monoproduct (Subutex and generics): reserved for pregnancy and documented naloxone sensitivity (headache, nausea, anxiety, flushing reliably tied to dosing). Dosing is interchangeable with the combination product; you're only removing the naloxone.
• Long-acting injectables: Sublocade (subcutaneous, every 1–2 months) and Brixadi (subcutaneous, weekly or monthly) for patients who benefit from not handling a daily medication (adherence, diversion concerns, convenience). Patients are typically stabilized on sublingual product first.

Induction: Three Methods

Maintenance Dosing

• Typical range: 8–24 mg/day. Most patients need 16–24 mg to fully suppress cravings and withdrawal.
• ≥16 mg/day is the efficacy threshold that matches methadone. Underdosing is the most common reason buprenorphine "fails."
• Higher doses are associated with better retention and outcomes: do not reflexively minimize the dose.
• Titrate to a symptom, not a number: ask directly whether the patient still has cravings. If yes, go up. If cravings are gone and the patient is stable, you're there. Some patients do well below 12 mg; some need more than 24 mg.

Dosing Frequency

Buprenorphine's ~36-hour half-life means once-daily dosing suffices for craving/withdrawal control in most patients. Its analgesic effect is much shorter-lived, so patients with comorbid chronic pain may benefit from splitting the dose BID or TID.

Sublingual Technique (Teach This)

The film/tablet must dissolve under the tongue; it is not swallowed (oral bioavailability is poor due to first-pass metabolism; sublingual absorption is ~30%). Counsel: let it fully dissolve, then rinse the mouth with water, and avoid eating, drinking, or brushing teeth for ~1 hour afterward (mitigates the reported dental-erosion concern and protects absorption).

Part 4: Monitoring, The Schedule

Buprenorphine monitoring is light and behavioral, not lab-intensive. The tools are the urine screen, the PDMP, and the clinical conversation.

Urine Drug Screen (UDS)

• Frequency: roughly monthly, not every visit unless clinically indicated. Early and unstable patients warrant more.
• Philosophy: the UDS is an assessment tool, like a depression rating scale, not a gatekeeping test. A positive opioid or cocaine screen opens a conversation about dose, supports, or level of care; it is not grounds for discharge. Discharging patients for using is discharging them toward overdose.
• A negative buprenorphine screen (the drug you prescribed isn't present) warrants a nonjudgmental conversation: it may signal diversion, but this is less dangerous than diversion of other controlled substances, and the honest answer might be a dosing or adherence issue.
• Directly observed collection has largely been abandoned (invasive, low added value). Outside labs are fine.

Prescription Monitoring & Prescribing Cadence

• Check the PDMP periodically (e.g., every 2–3 months) to detect multiple-prescriber sourcing.
• Scripts are capped at 30 days, so the patient is seen at least monthly; weekly early on while you dial in the dose.
• Missed appointments: a practical nudge is a shortened script (e.g., a 4-day supply instead of 30) as a reminder, with a clear discharge policy (commonly 3 no-shows) stated up front in the treatment agreement.

Liver

• Buprenorphine is acceptable with liver enzymes <3× ULN. Routine LFT surveillance is not mandated in healthy patients; check if hepatic disease is known or suspected.
• No data in cirrhosis/liver failure: weigh risk/benefit individually there.
• Ensure hepatitis A & B vaccination.

What You Are Not Required to Do

No routine ECG, no routine CBC, no routine electrolytes/renal panel in otherwise healthy patients. Buprenorphine does not carry methadone's QT-prolongation baggage in the way that would mandate serial ECGs.

Part 5: Side Effects and How to Manage Them

The governing principle: buprenorphine's side effects are mostly the predictable opioid class effects (constipation, sweating, sedation) and they are manageable and often self-limited. The one you address proactively on day one is constipation.

Constipation (near-universal; manage from the start)

An opioid-receptor effect; expect it in essentially every patient.

Management: start a standing bowel regimen for everyone.

• Avoid bulk-forming agents (psyllium/fiber): they worsen opioid constipation.
• Use an osmotic laxative (polyethylene glycol/MiraLAX) plus a stool softener (docusate), with PRN stimulant (senna or bisacodyl) as needed.
• Adequate hydration and activity.

Sweating, Headache

Common, generally mild opioid-class effects. Reassure; they often attenuate over time. Symptomatic management as needed.

Sedation

• Usually resolves over the first few weeks.
• If persistent: minimize other sedating medications, and move the buprenorphine dose to the evening.
• Persistent daytime sedation should also prompt a look for concurrent CNS depressants.

Naloxone Sensitivity (rare, combination product only)

A minority of patients get headache, nausea, anxiety, or flushing immediately after sublingual buprenorphine/naloxone. If the temporal relationship is reliable, switch to the monoproduct (Subutex).

Nausea

Usually transient; more prominent if managing precipitated withdrawal. Ondansetron 4 mg PRN is a clean choice.

Dental Issues (reported, mechanism debated)

Possibly related to prolonged sublingual acid exposure. Rinse with water after the film dissolves; no eating/drinking/brushing for ~1 hour; regular dental follow-up.

Part 6: Overdose and Toxicity, Where the Ceiling Helps and Where It Doesn't

The Ceiling Effect (the safety story)

Because buprenorphine only partially activates the mu receptor, respiratory depression plateaus: beyond a certain dose, more drug does not further suppress breathing. Taken alone, buprenorphine is far less lethal in overdose than methadone or heroin. This is the pharmacologic heart of why it can be prescribed for home use.

The Black Box Warning (where the ceiling doesn't protect you)

But, and this is the clinically important nuance, the warning is not a mandate to withhold buprenorphine from patients who use benzodiazepines. The relevant comparison is benzodiazepine + buprenorphine versus benzodiazepine + street fentanyl. The buprenorphine option is clearly safer. The strategy is to minimize benzodiazepine use, counsel on alcohol, document your risk-benefit reasoning, and not deny treatment.

A Naloxone Caveat

If a buprenorphine-involved overdose does occur (almost always in combination with other depressants), naloxone rescue may be less effective because buprenorphine binds the receptor so tightly. Higher or repeated naloxone doses and supportive care may be required. Every OUD patient and their household should have naloxone on hand regardless.

Precipitated Withdrawal (a toxicity of timing, not dose)

Reviewed in Part 3 and the confidence section. It is not directly lethal, but it is severe (vomiting, diarrhea, diaphoresis, myalgias, extreme anxiety and restlessness) and its real danger is that the patient abandons treatment and returns to street use, where overdose lives. Prevent it with COWS ≥8–10 timing; treat it by giving more buprenorphine (flood the receptors, often the full 24 mg) plus symptomatic support:

• Clonidine 0.1–0.2 mg PRN (autonomic symptoms)
• Ondansetron 4 mg (nausea)
• Trazodone 50 mg (sleep/agitation)
• Hydroxyzine 50 mg (anxiety)
• Lorazepam 0.5–1 mg PRN (severe anxiety; used cautiously given the respiratory synergy)

If precipitated withdrawal is genuinely intolerable and buprenorphine can't be rescued, the fallback is to pivot to methadone (an initial ~20–30 mg, up to ~10 mg more, capped near 40 mg in 24 hours) and refer to a federally recognized OTP.

Part 7: Drug Interactions

The Interaction That Matters Most: CNS Depressants

Benzodiazepines, alcohol, and other CNS depressants: synergistic respiratory depression (the black box). This is the highest-significance interaction. Manage, don't reflexively avoid: minimize benzodiazepines, counsel on alcohol abstinence, monitor, and document. Remember that many OUD patients carry trauma and legitimate anxiety histories; assess benzodiazepine use thoughtfully rather than issuing ultimatums.

CYP3A4 Metabolism

Buprenorphine is metabolized primarily by hepatic CYP3A4 (to the active metabolite norbuprenorphine).

• Strong CYP3A4 inhibitors (e.g., some azole antifungals, certain macrolides, ritonavir-boosted regimens, some protease inhibitors) can raise buprenorphine levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can lower buprenorphine levels, potentially unmasking cravings/withdrawal.
• In practice, buprenorphine's ceiling makes these interactions less dangerous than the equivalent interactions would be with a full agonist, but be alert when starting or stopping a potent 3A4 modulator: watch for over-sedation (inhibitors) or breakthrough withdrawal (inducers) and adjust.

Stimulants

Less concern than benzodiazepines; no major pharmacokinetic interaction. Co-use of stimulants is a reason to discuss stimulant-use-disorder treatment, not to withhold buprenorphine.

Naloxone (within the combination product)

Sublingually, naloxone is inert (poor bioavailability). Its only pharmacologic role is anti-abuse: if injected, it precipitates withdrawal. Switch to the monoproduct only for genuine naloxone sensitivity.

Other Opioids / Acute Pain

Buprenorphine's high receptor affinity and partial agonism blunt the analgesia of added full agonists, complicating acute pain management. For planned surgery/labor, coordinate a pain plan in advance (regional/epidural techniques and, when needed, full agonists layered on: an area of limited but evolving evidence). Do not simply stop buprenorphine and hope.

Methadone Transitions

No major pharmacokinetic obstacle; the microinduction approach handles the switch smoothly by avoiding the precipitated-withdrawal window.

Part 8: Special Populations

Pregnancy

Buprenorphine is a preferred agent for OUD in pregnancy, and the framework is well established:

• Product: switch from the combination product to the monoproduct (Subutex) when pregnancy is known; remove the naloxone.
• If already stable on methadone: generally continue methadone; don't switch a stable patient mid-pregnancy.
• Neonatal outcomes: the MOTHER Study (Jones, NEJM 2010) found buprenorphine associated with better neonatal outcomes than methadone: less severe neonatal opioid withdrawal, better Apgar measures.
• Timing of any changes: the second trimester is optimal (lower miscarriage/preterm-labor risk); coordinate closely with obstetrics.
• Dosing: requirements may rise, especially in the third trimester (increased volume of distribution/clearance); monitor cravings and titrate.
• Delivery/postpartum: plan analgesia in advance (epidurals in labor; full agonists layered for postpartum pain as needed). Anticipate and manage neonatal opioid withdrawal with the pediatric team.

The overarching principle mirrors all of OUD care: untreated OUD in pregnancy is far more dangerous to mother and fetus than buprenorphine. Treat.

Lactation

Buprenorphine is excreted into breast milk in negligible amounts, and breastfeeding is generally regarded as compatible with maintenance therapy (consistent with AAP guidance), assuming the mother is stable and not using illicit drugs. Coordinate with pediatrics and monitor the infant.

Adolescents

• FDA labeling supports use from age 16+; younger use is off-label with emerging support.
• Adolescents with OUD face grave risks: overdose, HIV, suicide, death. In randomized data, maintenance buprenorphine outperformed a short (14-day) taper for treatment engagement in 15–21-year-olds.
• Long-term physiologic data are lacking, so the decision is an explicit risk-benefit conversation: the well-documented dangers of untreated dependence versus the unknowns of long-term maintenance in a developing patient. Given the mortality stakes, engagement usually wins.

Elderly

• No specific dose adjustment; use standard dosing.
• Watch for additive sedation, falls, and respiratory depression with concurrent CNS depressants, and account for age-related polypharmacy.

Hepatic Impairment

• Acceptable with enzymes <3× ULN.
• Cirrhosis/liver failure: insufficient data; individualized risk-benefit; consider the monoproduct (avoid unnecessary naloxone) and monitor. Ensure hepatitis A/B vaccination.

Renal Impairment

• Buprenorphine is hepatically metabolized; no renal dose adjustment is generally required. This is a genuine advantage in patients with kidney disease.

Part 9: Discontinuation, The Riskiest Thing You Can Do

Here is the counterintuitive truth at the center of OUD treatment: stopping the medication is more dangerous than staying on it, by a wide margin.

This inverts the intuition many patients (and some clinicians) bring to treatment, the sense that the "real" goal is getting off the medication. Reframe it explicitly: staying on buprenorphine is not a failure of recovery; it is recovery, and it is keeping the patient alive.

If a Stable Patient Nonetheless Insists on Stopping

• Taper, never stop abruptly. Slower tapers relapse less.
• Reduce by no more than ~20% at any one step, spacing steps out.
• Check in frequently, adjust the schedule to symptoms, and be ready to halt or reverse the taper.
• Ensure intensive psychosocial support through the taper and after: relapse risk is highest right after cessation, and that is exactly when overdose risk spikes.
• Confirm the patient and household have naloxone.

The message to give patients: "The evidence is clear that staying on this medication keeps you safer. If you ever want to come off, we do it slowly and together, with a plan to restart the moment you need it. Stopping on your own is one of the most dangerous things you can do."

Part 10: Buprenorphine vs Methadone vs Naltrexone

All three are legitimate; the choice is individualized.

vs Methadone

Methadone's edge: for very high-tolerance, high-dose full-agonist users, a full agonist with no efficacy ceiling may control cravings when buprenorphine can't.

vs Naltrexone

• Naltrexone is a full mu-antagonist: it blocks opioids rather than partially activating the receptor. Oral naltrexone is passive (works only if actually taken); the monthly injectable (Vivitrol, 380 mg IM) removes the daily-adherence problem.
• The induction hurdle is the opposite problem: naltrexone requires full opioid detoxification first (a ~7–10 day opioid-free washout), or it precipitates withdrawal. That detox window is itself a period of high dropout and overdose risk.
• Buprenorphine generally wins on engagement and margin of safety: it relieves withdrawal and cravings actively, doesn't require prior full detox, and retains patients better. Naltrexone suits highly motivated patients or those who refuse any agonist (e.g., certain occupational or personal-abstinence requirements).

Mechanism: The Short Version

Buprenorphine is a partial agonist at the mu-opioid receptor (high binding affinity, low intrinsic activity) and a full antagonist at the kappa-opioid receptor. Three consequences of that profile drive everything clinically important:

1. The ceiling effect. Partial mu-activation plateaus, so respiratory depression (and euphoria) cap out with rising dose, the source of its safety advantage over full agonists and the reason it's suitable for take-home use.
2. High affinity + long half-life (~36 hours). Buprenorphine grips the receptor tightly and lingers, giving once-daily craving/withdrawal control and blunting the effect of other opioids that try to compete for the receptor.
3. Precipitated withdrawal. That same high affinity means that if buprenorphine is introduced while a full agonist still occupies receptors, it displaces the stronger agonist and substitutes weaker partial activation, dropping the patient into acute withdrawal. This is why induction timing (COWS ≥8–10) is the whole game.

Metabolism is hepatic via CYP3A4 to the active metabolite norbuprenorphine (hence the 3A4 interactions and the lack of a renal dose adjustment). Sublingual bioavailability is ~30%; the drug is essentially inactive if swallowed. The naloxone in the combination product contributes nothing sublingually; it exists solely to punish injection.

Bedside Cheat Sheet